Activist Investor Demands Board Shakeup at Novartis After $12B Drug Flop
NVS is trading near its 52-week low of $121.57 (14% above the low).
Summary
Artisan Partners' David Samra is publicly pressuring Novartis Chairman Giovanni Caforio to overhaul the board, citing poor M&A oversight after two Phase III failures in a week. The $12B Avidity deal for del-desiran and the pelacarsen miss with Ionis have wiped out significant value, and Samra points to the Morphosys write-off as further evidence of failed dealmaking. This is the first public activist challenge to Novartis governance following the trial setbacks, adding a new layer of pressure beyond the stock's 11% monthly decline. Watch for any board response or additional shareholder support for Samra's demands.
At the time of this announcement, NVS was trading at $138.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $252.3B. The 52-week trading range was $121.57 to $170.46. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.